Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:ASND NYSE:RDY NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$30.69-2.6%$21.17$9.57▼$31.67$4.24B12.71 million shs4.94 million shsASNDAscendis Pharma A/S$197.68-0.8%$187.70$118.03▼$208.16$12.10B0.39341,201 shs688,058 shsRDYDr. Reddy's Laboratories$14.86+0.2%$14.34$12.26▼$16.19$12.42B0.32749,900 shs922,413 shsSMMTSummit Therapeutics$18.89-1.8%$24.89$15.55▼$36.91$14.03B-1.025.14 million shs9.20 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+3.26%+47.90%+100.33%+47.69%ASNDAscendis Pharma A/S0.00%+1.07%+2.53%+11.75%+32.78%RDYDr. Reddy's Laboratories0.00%+1.43%+3.21%-2.38%-5.70%SMMTSummit Therapeutics0.00%-0.26%-27.37%-8.12%-23.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$30.69-2.6%$21.17$9.57▼$31.67$4.24B12.71 million shs4.94 million shsASNDAscendis Pharma A/S$197.68-0.8%$187.70$118.03▼$208.16$12.10B0.39341,201 shs688,058 shsRDYDr. Reddy's Laboratories$14.86+0.2%$14.34$12.26▼$16.19$12.42B0.32749,900 shs922,413 shsSMMTSummit Therapeutics$18.89-1.8%$24.89$15.55▼$36.91$14.03B-1.025.14 million shs9.20 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+3.26%+47.90%+100.33%+47.69%ASNDAscendis Pharma A/S0.00%+1.07%+2.53%+11.75%+32.78%RDYDr. Reddy's Laboratories0.00%+1.43%+3.21%-2.38%-5.70%SMMTSummit Therapeutics0.00%-0.26%-27.37%-8.12%-23.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 3.00Buy$43.1440.58% UpsideASNDAscendis Pharma A/S 3.00Buy$244.3623.61% UpsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9514.06% UpsideSMMTSummit Therapeutics 2.56Moderate Buy$31.8768.70% UpsideCurrent Analyst Ratings BreakdownLatest ARWR, SMMT, RDY, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025SMMTSummit TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$13.009/16/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.009/16/2025SMMTSummit TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$13.009/16/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/8/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.009/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/2/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$227.00 ➝ $230.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$572.98M7.41N/AN/A$1.54 per share19.93ASNDAscendis Pharma A/S$490.75M24.66N/AN/A($1.88) per share-105.15RDYDr. Reddy's Laboratories$3.81B3.26$1.03 per share14.40$4.73 per share3.14SMMTSummit TherapeuticsN/AN/AN/AN/A$0.53 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$5.16N/A823.67N/A-54.94%N/A-24.31%11/13/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.5218.126.0116.99%17.25%11.63%11/4/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)Latest ARWR, SMMT, RDY, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.47%N/A10.61%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest ARWR, SMMT, RDY, and ASND DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/30/2025RDYDr. Reddy's Laboratoriesannual$0.09150.623832253665189%7/25/20257/10/20258/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87ASNDAscendis Pharma A/SN/A1.020.69RDYDr. Reddy's Laboratories0.011.891.36SMMTSummit TherapeuticsN/A5.135.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%ASNDAscendis Pharma A/SN/ARDYDr. Reddy's Laboratories3.85%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%ASNDAscendis Pharma A/S40.00%RDYDr. Reddy's Laboratories2.00%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableASNDAscendis Pharma A/S1,01761.21 million36.73 millionOptionableRDYDr. Reddy's Laboratories27,811834.92 million818.23 millionOptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionableARWR, SMMT, RDY, and ASND HeadlinesRecent News About These CompaniesWealth Management Partners LLC Cuts Stock Position in Summit Therapeutics PLC $SMMTSeptember 21 at 6:26 AM | marketbeat.comVoya Investment Management LLC Lowers Stock Position in Summit Therapeutics PLC $SMMTSeptember 20 at 3:20 AM | marketbeat.comJim Cramer on Summit Therapeutics: “We’re Going to Have to Move On”September 19 at 8:45 AM | msn.comBarclays Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Strong Sell"September 19 at 6:47 AM | marketbeat.comRockland Trust Co. Buys Shares of 400,000 Summit Therapeutics PLC $SMMTSeptember 19 at 5:32 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 18 at 10:00 AM | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated at BarclaysSeptember 18 at 8:14 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at BarclaysSeptember 18 at 3:11 AM | americanbankingnews.comSummit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough PotentialSeptember 17, 2025 | fxempire.comFSummit Therapeutics (NASDAQ:SMMT) Receives Buy Rating from HC WainwrightSeptember 17, 2025 | marketbeat.comFocus Partners Wealth Boosts Stake in Summit Therapeutics PLC $SMMTSeptember 17, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT)September 17, 2025 | americanbankingnews.comSummit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 16, 2025 | globenewswire.comInsiders Are Aggressively Buying These 5 StocksSeptember 16, 2025 | 247wallst.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up Following Insider Buying ActivitySeptember 14, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 14, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Acquires 333,394 SharesSeptember 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Buys 333,394 SharesSeptember 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 13, 2025 | prnewswire.comSiren L.L.C. Takes $13.41 Million Position in Summit Therapeutics PLC $SMMTSeptember 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up After Insider Buying ActivitySeptember 13, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARWR, SMMT, RDY, and ASND Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$30.69 -0.82 (-2.60%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$31.08 +0.39 (+1.26%) As of 09/19/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Ascendis Pharma A/S NASDAQ:ASND$197.68 -1.69 (-0.85%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$196.04 -1.64 (-0.83%) As of 09/19/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Dr. Reddy's Laboratories NYSE:RDY$14.86 +0.03 (+0.20%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$14.86 0.00 (-0.03%) As of 09/19/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Summit Therapeutics NASDAQ:SMMT$18.89 -0.34 (-1.77%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$19.05 +0.16 (+0.87%) As of 09/19/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
